0645 Revision and Explants Rates by Year for Closed Loop Upper Airway Stimulation

Abstract Introduction As part of the approval to market and sell implanted medical devices, regulatory bodies mandate device manufacturers to collect data for any surgical revisions or explants required by their device. Combining this post market surveillance data with total implant counts can provide the real world rates for these procedures and help determine whether the safety data produced in a pivotal approval trial holds up in broad clinical applications. We calculated the cumulative revision and explant rates for the closed loop upper airway stimulation device produced by Inspire Medical Inc. (Golden Valley, MN USA). Methods Counts of revision and explant procedures were extracted from Inspire Medical Incorporated’s post market surveillance data. Procedures were grouped by calendar year of initial implant, and rates were calculated using the corresponding year’s total implant count. Implants prior to 2018 were excluded. Results Within 3 years of implant, cumulative revision procedures - shown as percent (implant year) - were 5.5% (2018), 3.4% (2019), 3.6% (2020), 2.6% (2021), and 2.6% (2022). Cumulative explant rates for this period were 2.4% (2018), 2.1% (2019), 2.5% (2020), 1.5% (2021), and 1.5% (2022). Within five years of implant the cumulative revision rates were 8.5% (2018), 5% (2019), and 4.8% (2020). Cumulative explant rates for this period were 4.3% (2018), 3.4% (2019), and 3.1% (2020). Conclusion Overall, the risk of surgical revision or explant of the closed loop upper airway stimulator is low. That the explant rates are lower than the revision rates suggest the patients receive a clinical benefit from the device and prefer to correct the underlying problem rather than remove the device. This analysis shows a trend of decreased events by later implant years, suggesting that improvements in the device components as well as surgical training have reduced patient risk. Support (if any) This work was funded by Inspire Medical Incorporated.

Authors

Institutions

Publication Details

Journal
SLEEP
Published
2026-05-01
DOI
https://doi.org/10.1093/sleep/zsag091.0644
Primary Topic
Voice and Speech Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

0645 Revision and Explants Rates by Year for Closed Loop Upper Airway Stimulation

Andrea Rasmussen, Nicole Karsky, Mark Aloia, Israel Byrd
SLEEP
Voice and Speech Disorders
article

0645 Revision and Explants Rates by Year for Closed Loop Upper Airway Stimulation

Andrea Rasmussen, Nicole Karsky, Mark Aloia, Israel Byrd
article en

Abstract

Abstract Introduction As part of the approval to market and sell implanted medical devices, regulatory bodies mandate device manufacturers to collect data for any surgical revisions or explants required by their device. Combining this post market surveillance data with total implant counts can provide the real world rates for these procedures and help determine whether the safety data produced in a pivotal approval trial holds up in broad clinical applications. We calculated the cumulative revision and explant rates for the closed loop upper airway stimulation device produced by Inspire Medical Inc. (Golden Valley, MN USA). Methods Counts of revision and explant procedures were extracted from Inspire Medical Incorporated’s post market surveillance data. Procedures were grouped by calendar year of initial implant, and rates were calculated using the corresponding year’s total implant count. Implants prior to 2018 were excluded. Results Within 3 years of implant, cumulative revision procedures - shown as percent (implant year) - were 5.5% (2018), 3.4% (2019), 3.6% (2020), 2.6% (2021), and 2.6% (2022). Cumulative explant rates for this period were 2.4% (2018), 2.1% (2019), 2.5% (2020), 1.5% (2021), and 1.5% (2022). Within five years of implant the cumulative revision rates were 8.5% (2018), 5% (2019), and 4.8% (2020). Cumulative explant rates for this period were 4.3% (2018), 3.4% (2019), and 3.1% (2020). Conclusion Overall, the risk of surgical revision or explant of the closed loop upper airway stimulator is low. That the explant rates are lower than the revision rates suggest the patients receive a clinical benefit from the device and prefer to correct the underlying problem rather than remove the device. This analysis shows a trend of decreased events by later implant years, suggesting that improvements in the device components as well as surgical training have reduced patient risk. Support (if any) This work was funded by Inspire Medical Incorporated.

SLEEPVol. 49(Supplement_1)
Inspire Medical Systems (United States) (US)
Partnerships for the goals
Openalex Percentile: Top 7%
Voice and Speech Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.